持续推动关键核心技术攻坚。瞄准光子、新能源、新材料、生物医药等重点产业链发展的"难点、 堵点、卡点"，以企业需求为牵引，部署实施关键核心技术攻关计划，支持高校、院所、企业联合攻 关，集中优势科研力量，突破一批制约产业升级的技术瓶颈，实现科技供给与产业需求精准对接、深度 融合。 1月14日，记者从省科技厅获悉：陕西立足基础研究和原始创新核心优势，通过完善实验室体系、 强化基础研究投入、培育青年人才、优化奖励导向等举措夯实创新根基，同时锚定新质生产力培育目 标，优化科研项目布局，加强关键核心技术攻关。 省科技厅相关负责人介绍，近年来，陕西完成在陕全国重点实验室重组，建成5个陕西实验室、235 个省重点实验室，构建起特色鲜明的实验室体系；基础研究投入持续加大，2024年首设国家自然科学基 金区域创新发展联合基金（陕西），2025年获批国家自然科学基金2848项，资助经费16.66亿元，推动 高水平成果持续涌现。在此基础上，陕西将进一步优化科研项目布局，加强关键核心技术攻关，促进科 技成果转化，加快培育发展新质生产力。 加强基础研究和应用基础研究。陕西将加大基础研究项目长期稳定投入力度，完善科研经费"包干 制" 等支 ...

Core Insights - The financial data for 2025 indicates a robust performance, with new loans totaling 16.27 trillion yuan, reflecting the effectiveness of moderately loose monetary policies and sustained credit demand from businesses and households [1][2] - The total social financing scale increased by 35.6 trillion yuan, with M2 money supply exceeding 340 trillion yuan and RMB loan balance surpassing 270 trillion yuan, showcasing a solid financial system supporting economic stability and internal demand [1] Monetary Policy Impact - The past year saw precise monetary policy actions, including a 0.5 percentage point reduction in the reserve requirement ratio and a 0.1 percentage point cut in policy interest rates, which have led to reasonable growth in social financing and maintained low loan interest rates [1][3] - By December 2025, the weighted average interest rate for newly issued corporate loans was around 3.1%, a decrease of 2.5 percentage points since the second half of 2018, reducing financing costs for businesses [1] Loan Distribution and Economic Trends - In 2025, new loans to enterprises amounted to 15.47 trillion yuan, indicating that over 90% of new loans were aligned with corporate needs, with more than half of these being medium to long-term loans, reflecting stable expectations for future development [2] - Key sectors attracting loans included technology (11.5% growth), green initiatives (23% growth), inclusive finance (10.3% growth), elderly care (60.2% growth), and digital fields (14.6% growth), all surpassing the overall loan growth rate [2] Structural Policy Enhancements - Continuous optimization of structural monetary policy tools has been observed, including increased quotas for loans supporting technological innovation and agricultural financing, as well as the introduction of risk-sharing tools for technology innovation bonds [3] - The financial sector is supporting rapid growth in industries such as humanoid robotics, biomedicine, and high-end equipment manufacturing, contributing to the high-quality development of the economy [3] Future Outlook - The People's Bank of China has committed to maintaining a moderately loose monetary policy in 2026, focusing on counter-cyclical adjustments to expand domestic demand and optimize supply, thereby fostering a stable economic growth environment [3] - As financial support quality improves, the alignment between financial supply and high-quality development of the real economy is expected to strengthen, contributing to a positive economic trajectory [3]

Core Insights - The Qingdao Free Trade Zone has strategically developed the life and health industry, with 69 projects, 5 provincial-level R&D institutions, and over 3,700 talents in the sector [1] Group 1: Industry Development - The Qingdao Free Trade Zone has established a strong foundation for the life and health industry, focusing on basic research, applied research, and industrial transformation [1] - The region has successfully introduced over 10 biopharmaceutical companies, leveraging leading enterprises to create a 288,000 square meter development platform for the life and health industry [1] Group 2: Technological Innovation - Breakthroughs in various cutting-edge technology fields have been achieved, including over 100 authorized invention patents in molecular breeding and more than 200 PCT international invention patents [1] - The global first immune anti-tumor marine polysaccharide new drug BG136 is expected to release its phase II clinical report in March [1] Group 3: Future Plans - The Qingdao Free Trade Zone aims to introduce 18 globally leading projects in exosome and cell transformation applications by 2025, doubling the number of projects within two years [1] - The focus will be on exploring application scenarios and optimizing the life and health industry ecosystem to better serve enterprise development [2]

Group 1 - The Qingdao Free Trade Zone has strategically planned the development of the life and health industry, achieving significant progress with 69 projects and the establishment of 5 provincial-level research institutions [1] - The industry has attracted over 3,700 talents and has been recognized for its potential in gene technology, with the gene technology industry cluster included in Shandong Province's future industry clusters [1] - The global first immune anti-tumor marine polysaccharide new drug BG136 is expected to release its phase II clinical report in March, showcasing the collaborative innovation efforts of various research institutions [1] Group 2 - The Qingdao Free Trade Zone has made breakthroughs in multiple cutting-edge technology fields, with over 100 invention patents authorized and more than 200 PCT international invention patents authorized [1] - Three leading enterprises, Guoxin Pharmaceutical, BGI, and Qingyuan, have established operations in the zone, which has developed a 288,000 square meter facility for the life and health industry [1] - The zone aims to introduce 18 new projects related to exosomes and cell transformation applications by 2025, indicating a doubling of project numbers within two years [1][2]

证券代码：603566 证券简称：普莱柯 公告编号：2026-003 关于预计2026年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 是否需要提交股东会审议：否 ● 日常关联交易对上市公司的影响：普莱柯生物工程股份有限公司（以下简称"普莱柯"或"公司"）2026 年度日常关联交易预计是基于公司日常经营活动实际需要进行的合理估计，有利于公司业务的开展，不 会损害公司和股东、特别是中小股东的利益，公司主营业务不会因此对关联人形成较大依赖，亦不会对 公司独立性构成影响。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 普莱柯生物工程股份有限公司 1、2026年1月15日，公司第五届董事会第二十二次会议审议通过了《关于预计2026年度日常关联交易的 议案》，关联董事张许科先生、秦德超先生、胡伟先生、宋永军先生、裴莲凤女士、赵锐先生回避表 决。 2、公司2026年度预计日常关联交易金额3,924.00万元，占公司2024年度经审计净资产的1.49%，在董事 会决策权限范围内，无需提 ...

Group 1 - The Beijing Stock Exchange (BSE) has accelerated its listing review process, with three companies successfully passing the review in January 2026, continuing the trend from Q4 2025 [1][2] - A total of 25 companies were reviewed by the BSE from November to December 2025, with 23 companies successfully approved [1] - The companies that passed the review include Zhoushan Chenguang Electric Machine Co., Guangdong Banzhe Chuangke Electric Co., and Mingguang Ruier Jinda Technology Co., all of which are in high-end manufacturing or strategic emerging sectors [1][2] Group 2 - Upcoming review meetings for additional companies are scheduled for January 16 and January 21, 2026, indicating ongoing support for high-tech and high-end manufacturing industries [2] - The BSE's focus on core technology and industrial value is expected to empower companies in hard technology and niche markets to go public [2] - The frequency of new stock issuance meetings has increased since Q3 2025, suggesting a strong outlook for high-quality expansion and liquidity improvement at the BSE [3] Group 3 - The initial public offerings (IPOs) of three companies have already begun in 2026, with significant investor interest, as evidenced by the high subscription rates for Zhejiang Kema Friction Materials Co. [3] - The "money-making effect" of new stocks on the BSE has been notable in 2025, leading to increased investor participation in new stock subscriptions [3] - With the acceleration of the review process, the supply of new stocks in 2026 is expected to increase, providing more opportunities for investors [3]

Group 1 - The core viewpoint of the news is the significant progress made by Hainan Province in market supervision and intellectual property protection during the "14th Five-Year Plan" period, emphasizing convenience and innovation [1][2] - Hainan Province has implemented a simplified market access approval process, leading to the addition of 2.4282 million new business entities, with foreign investment enterprises growing at the fastest rate in the country [1] - The province has pioneered the "Hainan Model" for consumer confidence, establishing over 150,000 trusted consumption units across more than 20 industries, including tourism and dining [1] Group 2 - The Hainan Provincial Intellectual Property Office has established a comprehensive protection system focusing on rapid, strict, and collaborative measures, with three innovative practices recognized as national examples [2] - A new intellectual property protection regulation has been introduced, aligning with international standards to enhance the protection framework in the free trade port [2] - The province is promoting innovation through intellectual property by creating a special zone in Sanya for the "South Breeding Industry" and "Deep Sea Technology," offering 42 intellectual property service items to innovators [2]

Core Insights - The 44th JPMorgan Global Healthcare Conference highlighted a shift in focus for Chinese innovative drug companies from local innovation to global competitiveness, emphasizing international collaboration and commercialization strategies [1][5]. Group 1: Conference Overview - The JPMorgan conference took place from January 12 to January 15 in San Francisco, attracting numerous Hong Kong biotech companies [1]. - Participants reported a busy schedule filled with meetings, showcasing drug pipelines, discussing collaborations, and engaging with investors [2][3]. Group 2: Industry Trends - There is a noticeable increase in discussions surrounding Chinese innovation in the pharmaceutical sector, with a shift from skepticism to recognition of China's role in global drug development [4][5]. - Chinese companies are now presenting more substantial clinical data and international collaboration cases, moving beyond initial concept pitches [5]. Group 3: Company Strategies - Companies like InSilico Medicine and Eucure Biopharma are focusing on showcasing their unique technologies and clinical data to attract international partnerships and investments [3][5]. - The emphasis is on demonstrating global competitiveness and the ability to innovate, with a strategic shift towards international collaboration and long-term value creation [6][7]. Group 4: Future Directions - Chinese innovative drug companies aim to reshape international perceptions from being cost-driven to innovation-driven, integrating into the global biopharmaceutical innovation network [7]. - The industry is expected to produce globally influential pharmaceutical giants, reflecting the rapid growth and development of Chinese biotech firms [7].

Core Insights - The JPM Healthcare Conference 2026 highlighted a significant shift in the narrative surrounding Chinese innovation assets, which are increasingly recognized as critical components for multinational pharmaceutical companies' long-term growth strategies [4][5][24] - The conference emphasized the importance of clinical advancement efficiency and global development pace for Chinese pharmaceutical companies, marking the entry of their innovation pipelines into the core narratives of multinational firms as just the beginning [24] Group 1: Chinese Companies' Innovations - Chinese companies are now being integrated into the core strategies of multinational pharmaceutical firms, moving beyond previous "single-point licensing" narratives to being key contributors in oncology, neuroscience, and metabolic diseases [5][9] - Notable collaborations include SystImmune's BL-B01D1, which has a potential total deal value of $800 million with Bristol-Myers Squibb, and the KarXT project, which is prioritized for development in the psychiatric pipeline [5][7] - The partnership between 3SBio and Pfizer on the PD-1 and VEGF bispecific antibody SSGJ-707 is highlighted as a significant transaction, indicating its strategic importance in the next-generation oncology immunotherapy landscape [7][9] Group 2: Multinational Companies' Strategies - Multinational companies are focusing on a 2030 pricing framework, with strategic decisions revolving around which assets will shape the next industry reshuffle [10][24] - Bristol-Myers Squibb plans to launch 10 new drugs by 2030, emphasizing a multi-pillar approach to mitigate risks associated with patent cliffs [10][12] - Vertex Pharmaceuticals and Madrigal Pharmaceuticals are adopting a focused strategy on single disease areas, with Madrigal positioning itself as a leader in the MASH field and Vertex concentrating on cystic fibrosis and gene therapy [12][15] Group 3: Market Dynamics and Challenges - The second day of the conference shifted focus to practical execution challenges, including competition in metabolic diseases, patent expirations, and supply chain management [16][24] - Eli Lilly expressed uncertainty regarding the market performance of its oral GLP-1 candidate, while Novo Nordisk acknowledged significant competitive pressures and emphasized direct patient channel management [16][18] - Bayer updated its assessment of patent expirations for Xarelto and Eylea, indicating a gradual approach to managing revenue impacts while relying on new product launches for future growth [18][19] Group 4: Supply Chain and Manufacturing - The importance of local manufacturing capabilities was underscored, with Samsung Biologics discussing its U.S. production capacity to meet growing demand [21][24] - Companies like Teva and Sandoz are focusing on the strategic value of biosimilars in light of upcoming patent expirations, indicating a long-term structural adjustment rather than a short-term fix [19][21]

Core Viewpoint - Hainan Province is focusing on building a comprehensive intellectual property protection system during the 14th Five-Year Plan period, emphasizing rapid, strict, and collaborative protection to support the development of its characteristic advantageous industries [1][2][3][4] Group 1: Rapid Protection - Hainan has established two national-level intellectual property protection centers in Sanya and Haikou, facilitating a "fast track" for patent pre-examination in industries such as seed, marine, equipment manufacturing, and biomedicine [1] - The two protection centers have received a total of 4,700 patent pre-examination cases, reducing the average authorization period for invention patents from 16 months to 3 months, an acceleration of 80% [1] Group 2: Strict Protection - Hainan has implemented the "Hainan Free Trade Port Intellectual Property Protection Regulations," aligning with international high standards to create a robust intellectual property protection system [1] - The province has pioneered a "preliminary injunction" model for cross-border e-commerce intellectual property protection, allowing for the prohibition of production and sales of infringing products before case resolution [1] Group 3: Collaborative Protection - Hainan has developed an integrated collaborative protection mechanism for intellectual property, actively combating infringement and counterfeiting [2] - During the China International Consumer Products Expo, Hainan set up intellectual property protection workstations and service windows, employing a rapid response mechanism for pre-exhibition inspections of products [2] Group 4: Innovation and Economic Impact - Hainan is enhancing the innovation incentive, industrial support, and competitiveness of enterprises by focusing on industries like "South Seed Industry" and "Deep Sea Technology," establishing a knowledge property special zone in Sanya [3] - The province has created a comprehensive service demonstration area for intellectual property in Haikou, attracting leading enterprises and achieving national recognition for its small and medium-sized enterprise characteristic industrial cluster in biomedicine [3] Group 5: Support for SMEs - Hainan is addressing the financing challenges faced by small and medium-sized enterprises through intellectual property pledge financing, with the registration amount exceeding 14.7 billion yuan, a 202% increase from the previous five-year period [4] - This initiative has benefited over 140 small and medium-sized enterprises, effectively revitalizing intellectual property assets and injecting momentum into their development [4]